LSE:AVCT

Avacta presents first preclinical data from dual payload pre|CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and…

1 month ago

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025 10:00 ET  | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…

2 months ago